Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 705.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 579,562 shares of the company's stock after acquiring an additional 507,568 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.05% of Teva Pharmaceutical Industries worth $6,051,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Los Angeles Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $3,000,000. SG Americas Securities LLC increased its position in shares of Teva Pharmaceutical Industries by 31.7% during the fourth quarter. SG Americas Securities LLC now owns 544,878 shares of the company's stock valued at $5,689,000 after buying an additional 131,043 shares during the period. Wellington Management Group LLP increased its position in shares of Teva Pharmaceutical Industries by 42.2% during the third quarter. Wellington Management Group LLP now owns 344,587 shares of the company's stock valued at $3,515,000 after buying an additional 102,261 shares during the period. Gateway Investment Advisers LLC increased its position in shares of Teva Pharmaceutical Industries by 28.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company's stock valued at $437,000 after buying an additional 9,312 shares during the period. Finally, Camber Capital Management LP grew its holdings in Teva Pharmaceutical Industries by 183.3% in the second quarter. Camber Capital Management LP now owns 8,500,000 shares of the company's stock worth $64,005,000 after purchasing an additional 5,500,000 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now directly owns 382,590 shares of the company's stock, valued at $5,172,616.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now directly owns 382,590 shares of the company's stock, valued at $5,172,616.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now owns 10,676 shares of the company's stock, valued at approximately $132,062.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 390,738 shares of company stock valued at $5,132,766. Corporate insiders own 0.62% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded down $0.32 during midday trading on Friday, reaching $14.11. 10,247,157 shares of the company traded hands, compared to its average volume of 8,552,914. Teva Pharmaceutical Industries Limited has a 12 month low of $7.09 and a 12 month high of $14.45. The firm has a market capitalization of $15.82 billion, a price-to-earnings ratio of -30.02, a price-to-earnings-growth ratio of 1.63 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The business has a 50 day moving average of $13.02 and a two-hundred day moving average of $10.92.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TEVA shares. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $12.00 to $19.00 in a report on Monday, February 12th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective on the stock in a report on Friday, March 8th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Monday, February 5th. HSBC began coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, December 18th. They issued a "buy" rating and a $13.00 target price on the stock. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.